Expanding the use of abiraterone in prostate cancer: Is earlier always better?

Cancer Biol Ther. 2018 Feb 1;19(2):97-100. doi: 10.1080/15384047.2017.1394555. Epub 2017 Dec 8.

Authors

Keith T Schmidt¹, Ravi A Madan², William D Figg^{1

2}

Affiliations

¹ a Clinical Pharmacology Program, Office of the Clinical Director , National Cancer Institute, NIH , Bethesda , MD , USA.
² b Genitourinary Malignancies Branch, Center for Cancer Research , National Cancer Institute, NIH , Bethesda , MD , USA.

No abstract available

Publication types

Comment

MeSH terms

Androstenes*
Castration
Humans
Male
Prednisone*
Prostatic Neoplasms

Substances

Androstenes
abiraterone
Prednisone